Clinical Trials Logo

Pancreatic Gastrinoma clinical trials

View clinical trials related to Pancreatic Gastrinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03147768 Completed - Clinical trials for Pancreatic Neoplasms

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

LTW
Start date: January 1, 2018
Phase: Phase 1
Study type: Interventional

The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure. The hypothesis is that the laser tissue welding device is safe and effective in sealing the pancreas, thereby decreasing the blood loss (operative and post-operative), and pancreatic juice leakage for patients when the Laser Tissue Welding device is used after pancreatic resection.

NCT ID: NCT01229943 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor G2

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Start date: October 15, 2010
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well everolimus and octreotide acetate with or without bevacizumab works in treating patients with pancreatic neuroendocrine tumors that cannot be removed by surgery and have spread nearby or to other places in the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Octreotide acetate may interfere with and slow the growth of tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab and everolimus also may stop the growth of pancreatic neuroendocrine tumors by blocking blood flow to the tumor. It is not yet known whether giving everolimus and octreotide acetate together is more effective with or without bevacizumab in treating pancreatic neuroendocrine tumors.